ImCheck Therapeutics
Created in 2015
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
552 9,273Global tags
Activities
Technologies
Entity types
Location
31 Chemin Joseph Aiguier, CS 70071 13402, MARSEILLE Cedex 20, 13009 Marseille, France
Marseille
France
Employees
Scale: 11-50
Estimated: 56
SIREN
812428142Engaged corporates
32
15 22Added in Motherbase
4 years, 1 month ago
biotech Value proposition
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcellsOriginal language
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Imchecktherapeutics.com: Imcheck Therapeutics
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology.
https://imchecktherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Chambre de Commerce et d'Industrie Marseille-Provence Chamber of commerce, Government Administration | Chambre de Commerce et d'Industrie Marseille-Provence Chamber of commerce, Government Administration | Other 23 Oct 2024 | | |
 Direction Générale des Entreprises National and local authorities, Government Administration | Direction Générale des Entreprises National and local authorities, Government Administration | Other 23 Oct 2024 | | |
 Gustave Roussy Health, Hospitals and Health Care | Gustave Roussy Health, Hospitals and Health Care | Other 31 May 2024 | | |
 | Gouvernement | Other 16 Jun 2023 | | |
 | Ministère de la Santé | Other 16 Jun 2023 | | |
 NEFTYS Finance, Financial Services | NEFTYS Finance, Financial Services | Other 30 May 2024 | | |
 Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Other 16 Jun 2023 | | |
 La Coque Events Services | La Coque Events Services | Other 10 Mar 2023 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 21 Feb 2023 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Not capitalistic Not partnership Event 23 Sep 2023 | | |